For patients with psoriasis and Type 2 diabetes, the risk of developing chronic kidney disease (CKD) continued to rise ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

Patients with psoriatic arthritis who meet clinical criteria for minimal disease activity also tend to report good disease ...

An extended day in the sun can be anything but relaxing for those who develop polymorphous light eruption, an uncomfortable, ...

Just a few weeks after its approval in the UK, Bristol-Myers Squibb’s new oral psoriasis therapy Sotyktu has been recommended for routine NHS in England and Wales. The National ...